{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T13:31:24Z","timestamp":1786800684019,"version":"build-2736575974"},"reference-count":32,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Novartis Farmac\u00e9utica S.A., Spain"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Siponimod is approved in Europe for active secondary progressive multiple sclerosis (SPMS), but real-world data on its treatment patterns and outcomes in people with SPMS (pwSPMS) is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To assess the demographic and clinical characteristics, effectiveness, and safety of siponimod in pwSPMS in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Non-interventional\/observational, retrospective, multicenter study (28 centers).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients (\u2a7e18\u2009years) with active SPMS treated with siponimod in routine care were included. Retrospective clinical, radiological, and laboratory data were collected for patients up to 24\u2009months before and 12\u2009months after siponimod treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In total, 210 participants were included (mean age: 52.5\u2009\u00b1\u20098.6\u2009years; females: 71.0%). At treatment initiation, the mean Expanded Disability Status Scale (EDSS) score was 5.7\u2009\u00b1\u20091.2. The mean time since multiple sclerosis diagnosis and the median time since active SPMS diagnosis were 16.7\u2009\u00b1\u20098.9\u2009years and 1.3 (0.3; 4.4)\u2009years, respectively. Common comorbidities included psychiatric disorders and dyslipidemia (20.6%, each). Regarding working status, 55.9% with available information showed incapacity for work. Prior to siponimod, 44.3% received highly effective therapies: fingolimod (20.5%), rituximab (9.5%), ocrelizumab (5.2%), natalizumab (4.8%), and alemtuzumab (2.4%). After 1\u2009year, 82.8% of the patients remained stable in terms of disability progression, 94.3% were free of relapses, and 85.7% did not present radiological disease activity; 46.2% experienced adverse events, 8.6% experienced serious adverse events, and 26 (12.4%) patients discontinued permanently.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In the study cohort, pwSPMS had high disability scores and comorbidities; more than half were unable to work, and over 40% had previously received high-efficacy therapies. After 1\u2009year of siponimod treatment, most pwSPMS showed no signs of disease activity, with stabilized EDSS scores and relapses and new T2 or gadolinium-T1 lesions, as well as a favorable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562864261472650","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:06:15Z","timestamp":1786622775000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9221-5716","authenticated-orcid":false,"given":"Celia","family":"Oreja-Guevara","sequence":"first","affiliation":[{"name":"CSUR Multiple Sclerosis, Department of Neurology, Hospital Universitario Cl\u00ednico San Carlos, IdISCC, Madrid, Spain"},{"name":"Department of Medicine, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"G\u00f3mez-Est\u00e9vez","sequence":"additional","affiliation":[{"name":"CSUR Multiple Sclerosis, Department of Neurology, Hospital Cl\u00ednico San Carlos, IdISSC, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ag\u00fcado Garc\u00eda","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario de Burgos, Burgos, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Mart\u00edn Mart\u00ednez","sequence":"additional","affiliation":[{"name":"CSUR Esclerosis Multiple, Neurology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"G\u00f3mez Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario de C\u00e1ceres, C\u00e1ceres, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Gasc\u00f3n Gim\u00e9nez","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Cl\u00ednico de Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Ag\u00fcera Morales","sequence":"additional","affiliation":[{"name":"Instituto Maim\u00f3nides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba, Hospital Universitario Reina Sof\u00eda, Universidad de C\u00f3rdoba, C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Meca-Lallana","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario de La Princesa, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Barrero Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Neurology Department, Instituto Investigaci\u00f3n Biosanitaria, Hospital Universitario Cl\u00ednico San Cecilio, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Gonz\u00e1lez Quintanilla","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Romero Pinel","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitari de Bellvitge, IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Delgado Gil","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario Virgen de la Victoria, M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Dur\u00e1n Ferreras","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Blasco Qu\u00edlez","sequence":"additional","affiliation":[{"name":"Neuroimmunology Unit, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5050-9890","authenticated-orcid":false,"given":"Jose","family":"Meca-Lallana","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis CSUR and Clinical Neuroimmunology Unit, Neurology Department, Virgen de la Arrixaca Clinical University Hospital (IMIB-Arrixaca) and NICEM Cathedra-UCAM-San Antonio Catholic University, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamberto","family":"Landete Pascual","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario Dr. Peset, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Aladro-Benito","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario de Getafe, Getafe, Spain"},{"name":"Instituto Investigaci\u00f3n IdiPAZ, Universidad Europea de Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabas","family":"Boyero Dur\u00e1n","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario de Cruces, Barakaldo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gracia Gil","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital General Universitario de Albacete, Albacete, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bel\u00e9n","family":"Caminero Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Neurology Department, Complejo Hospitalario de \u00c1vila, \u00c1vila, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Tom\u00e1s","family":"Cano Orgaz","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital de Matar\u00f3, Matar\u00f3, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Eichau Madue\u00f1o","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Rosa","family":"Querol Pascual","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario de Badajoz, Badajoz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Otano Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7337-8384","authenticated-orcid":false,"given":"Ana Mar\u00eda","family":"Alonso Torres","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Regional Universitario de M\u00e1laga, M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Calles Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"L\u00f3pez Real","sequence":"additional","affiliation":[{"name":"Neurology Department, Complejo Hospitalario Universitario de A Coru\u00f1a, La Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Ares Luque","sequence":"additional","affiliation":[{"name":"Neurology Department, Complejo Asistencial Universitario de Le\u00f3n, Le\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Ram\u00f3n","family":"Lorenzo Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Ribeira Povisa, Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"G\u00f3mez Vicente","sequence":"additional","affiliation":[{"name":"Medical Department, Novartis Farmac\u00e9utica, S.A., Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"D\u00edaz S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000560"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13536"},{"key":"e_1_3_4_4_2","article-title":"Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies","volume":"4","author":"Coret F","year":"2018","unstructured":"Coret F, P\u00e9rez-Miralles FC, Gasc\u00f3n F, et al. Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies. Mult Scler J Exp Transl Clin 2018; 4: 2055217318783347.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.94.15_supplement.597"},{"key":"e_1_3_4_6_2","unstructured":"Siponimod (Mayzent\u00ae): EU summary of product characteristics https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mayzent-epar-product-information_en.pdf (2020 accessed 20 March 2025)."},{"key":"e_1_3_4_7_2","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Therapeutic positioning report of siponimod (Mayzent\u00ae) in secondary progressive multiple sclerosis https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/2021\/IPT_15-2021-Mayzent.pdf (2021 accessed 20 March 2025)."},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30475-6"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11166-z"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203952"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.2196\/19598"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104766"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-022-00219-3"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12206471"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231225711"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2024.0149"},{"key":"e_1_3_4_17_2","volume-title":"ACTRIMSForum 2024 (9th Annual Forum of the Americas Committee for Treatment and Research in Multiple Sclerosis)","author":"Hoffmann O SH","year":"2024","unstructured":"Hoffmann O SH, Klotz L, et al. Longitudinal observation of SPMS patients treated with siponimod in Germany\u2014three years interims data from real world study AMASIA. In: ACTRIMS Forum 2024 (9th Annual Forum of the Americas Committee for Treatment and Research in Multiple Sclerosis), Florida, 2024."},{"key":"e_1_3_4_18_2","volume-title":"40th congress of the European committee for treatment and research in multiple sclerosis","author":"Emanuele DA GB","year":"2024","unstructured":"Emanuele DA GB, Andr\u00e9 BM, et al. Characteristics of siponimod treated SPMS patients in Italy: real-world evidence from the ITASIA study. In: 40th congress of the European committee for treatment and research in multiple sclerosis. Denmark, 2024."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.931014"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540261.2017.1322555"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005302"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514564491"},{"key":"e_1_3_4_23_2","first-page":"483","article-title":"[Multiple sclerosis and pelviperineology: Urinary and sexual dysfunctions and pregnancy]","volume":"24","author":"De S\u00e8ze M","year":"2014","unstructured":"De S\u00e8ze M, Gam\u00e9 X. [Multiple sclerosis and pelviperineology: Urinary and sexual dysfunctions and pregnancy]. Prog Urol 2014; 24: 483\u2013494.","journal-title":"Prog Urol"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105787"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-023-00434-6"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/11596550-000000000-00000"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2016.11.008"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221083194"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww173"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh714"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-14-58"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.02.007"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1057\/9780230583993"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864261472650","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864261472650","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864261472650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T13:16:17Z","timestamp":1786799777000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864261472650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":32,"alternative-id":["10.1177\/17562864261472650"],"URL":"https:\/\/doi.org\/10.1177\/17562864261472650","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"17562864261472650"}}